SCHEMBL27159367

SCHEMBL27159367

Nc1nsc2ccc(Br)cc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
HSD17B10 Q99714 1/20 0.53
PDPK1 O15530 2/20 0.48
JAK2 O60674 2/20 0.48
CYP2A6 P11509 2/20 0.41
HTT P42858 1/20 0.41
EPAS1 Q99814 3/20 0.38
TLR4 O00206 1/20 0.38
ADRB2 P07550 1/20 0.35
BACE1 P56817 2/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CA2 P00918 1/20 0.33
PLG P00747 1/20 0.33
PLAU P00749 1/20 0.33
PLAT P00750 1/20 0.33
HRH4 Q9H3N8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11704181 0.79 MAPT (0.57) KDM4EALDH1A1MAPTHSD17B10HTT
SCHEMBL377405 0.76 MAPT (0.53) KDM4EALDH1A1MAPTHSD17B10TLR4
SCHEMBL30481262 0.76 EPAS1 (0.38) ALDH1A1PDPK1JAK2CYP2A6HTT
SCHEMBL10164894 0.76 EPAS1 (0.38) ALDH1A1PDPK1JAK2CYP2A6HTT
SCHEMBL2967038 0.76 EPAS1 (0.38) KDM4EALDH1A1MAPTPDPK1JAK2
SCHEMBL31586242 0.76 KDM4E (0.53) KDM4EALDH1A1MAPTHSD17B10TLR4
SCHEMBL7377529 0.76 KDM4E (0.53) KDM4EALDH1A1MAPTHSD17B10TLR4
SCHEMBL10968444 0.76 KDM4E (0.53) KDM4EALDH1A1MAPTHSD17B10CYP2A6
SCHEMBL280594 0.73 PLG (0.39) PDPK1JAK2CYP2A6EPAS1MEN1
SCHEMBL31586680 0.72 KDM4E (0.48) KDM4EALDH1A1MAPTHSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119585247-A Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain 赛特温治疗公司 2025-03-07 CN disclosed
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG CHEM, LTD. (KR) 2024-09-05 US disclosed
EP-4332106-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG Chem, Ltd. (KR) 2024-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR MAP3K20, SBK3, MAPKAPK2 KDM4E 1510/4885ALDH1A1 4634/4885MAPT 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.